ArticleClinical kidney journal2025
Occurrence and prognosis of chronic kidney disease in Denmark - a nationwide population-based cohort study.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark.Kidney medicine · 2026Article
- Parathyroid hormone and alkaline phosphatase are associated with fracture risk in non-dialysis-dependent chronic kidney disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- The Danish Lymphoid Cancer Research (DALY-CARE): Genetic Cohort Profile.Clinical epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Information on chronic kidney disease (CKD) epidemiology is essential for healthcare provision. Moreover, variation in CKD occurrence and prognosis may reveal unwarranted inequalities in healthcare. Therefore, we examined the nationwide incidence, prevalence, and mortality of laboratory-confirmed CKD in Denmark and assessed variation according to urbanicity. Methods: This nationwide cohort study utilized population-based laboratory data on estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (uACR) and included all adult (≥18 years) Danish residents without prevalent CKD on 1 January 2019. We estimated crude and standardized incidence rates, prevalences, and mortality rates of CKD overall and according to urbanicity categories. We standardized by age and sex, and by age, sex, diabetes, hypertension, and outpatient eGFR and uACR testing frequency. Results: The study included 4 157 059 adult Danish residents of whom 281 985 developed incident CKD during the 5-year study period. The CKD incidence rate was 14.5 [95% confidence interval (CI), 14.4-14.5] per 1000 person-years, and the CKD prevalence was 9.5% (95% CI, 9.5%-9.5%). The 5-year mortality was 24.9% (95% CI, 24.5%-25.3%). The crude CKD incidence, prevalence, and mortality varied across urbanicity categories; however, differences were largely accounted for by standardizing for age and sex. Conclusions: Chronic kidney disease affected nearly one in ten adults in Denmark, and one in four individuals with incident CKD died within 5 years. The occurrence and prognosis of CKD varied across urbanicity categories and was predominantly related to differences in demographics. This emphasizes the need for a targeted allocation of healthcare resources according to population demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.